{"entity":{"id":"nct07436728","kind":"trial","name":"A Study of TAK-505 in Adults With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of TAK-505 in advanced solid tumours, run by Takeda, now recruiting.","summary":"A Study of TAK-505 in Adults With Solid Tumors is a phase 1/2 interventional study registered as NCT07436728 by Takeda, with 151 participants planned, started 2026-05-11 and due to reach its primary completion in 2030-08-18. Interventions recorded: TAK-505.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07436728","url":"https://clinicaltrials.gov/study/NCT07436728"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["takeda"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07436728","phase":"1/2","setting":"A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","sponsor":"Takeda","enrolled":151,"outcomes":[]},"route":"/trials/nct07436728/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/"}]}}